tetano
Editor, Senior Moderator
Antiviral Res
. 2021 Jul 1;105126.
doi: 10.1016/j.antiviral.2021.105126. Online ahead of print.
Baloxavir-oseltamivir combination therapy inhibits the emergence of resistant substitutions in influenza A virus PA gene in a mouse model
Ji-Hyun Park[SUP] 1 [/SUP], Beomkyu Kim[SUP] 1 [/SUP], Khristine Joy C Antigua[SUP] 1 [/SUP], Ju Hwan Jeong[SUP] 1 [/SUP], Chang Il Kim[SUP] 1 [/SUP], Won-Suk Choi[SUP] 1 [/SUP], Sol Oh[SUP] 1 [/SUP], Chan Hyung Kim[SUP] 2 [/SUP], Eung-Gook Kim[SUP] 3 [/SUP], Young Ki Choi[SUP] 1 [/SUP], Yun Hee Baek[SUP] 4 [/SUP], Min-Suk Song[SUP] 5 [/SUP]
Affiliations
Abstract
Baloxavir marboxil (BXM) treatment-emergent polymerase acid (PA) I38X amino acid substitution (AAS) in the resistant variants of influenza viruses raise concerns regarding their emergence and spread. This study investigated the impact of 1 or 5 mg/kg BXM and 25 mg/kg oseltamivir phosphate (OS) (single or combination therapy) on the occurrence of resistance-related substitutions during the sequential lung-to-lung passages of AH1N1)pdm09 virus in mice. Deep sequencing analysis revealed that 67% (n = 4/6) of the population treated with BXM single therapy (1 or 5 mg/kg) possessed the treatment-emergent PA-I38X AAS variants (I38T, I38S, and I38V). Notably, BXM-OS combination therapy impeded PA-I38X AAS emergence. Although the doses utilized in the mouse model may not be directly translated into the clinically equivalent doses of each drugs, these findings offer insights toward alternative therapies to mitigate the emergence of influenza antiviral resistance.
Keywords: Antiviral susceptibility; Baloxavir; Combination therapy; Influenza; Oseltamivir; PA-I38X.
. 2021 Jul 1;105126.
doi: 10.1016/j.antiviral.2021.105126. Online ahead of print.
Baloxavir-oseltamivir combination therapy inhibits the emergence of resistant substitutions in influenza A virus PA gene in a mouse model
Ji-Hyun Park[SUP] 1 [/SUP], Beomkyu Kim[SUP] 1 [/SUP], Khristine Joy C Antigua[SUP] 1 [/SUP], Ju Hwan Jeong[SUP] 1 [/SUP], Chang Il Kim[SUP] 1 [/SUP], Won-Suk Choi[SUP] 1 [/SUP], Sol Oh[SUP] 1 [/SUP], Chan Hyung Kim[SUP] 2 [/SUP], Eung-Gook Kim[SUP] 3 [/SUP], Young Ki Choi[SUP] 1 [/SUP], Yun Hee Baek[SUP] 4 [/SUP], Min-Suk Song[SUP] 5 [/SUP]
Affiliations
- PMID: 34217753
- DOI: 10.1016/j.antiviral.2021.105126
Abstract
Baloxavir marboxil (BXM) treatment-emergent polymerase acid (PA) I38X amino acid substitution (AAS) in the resistant variants of influenza viruses raise concerns regarding their emergence and spread. This study investigated the impact of 1 or 5 mg/kg BXM and 25 mg/kg oseltamivir phosphate (OS) (single or combination therapy) on the occurrence of resistance-related substitutions during the sequential lung-to-lung passages of AH1N1)pdm09 virus in mice. Deep sequencing analysis revealed that 67% (n = 4/6) of the population treated with BXM single therapy (1 or 5 mg/kg) possessed the treatment-emergent PA-I38X AAS variants (I38T, I38S, and I38V). Notably, BXM-OS combination therapy impeded PA-I38X AAS emergence. Although the doses utilized in the mouse model may not be directly translated into the clinically equivalent doses of each drugs, these findings offer insights toward alternative therapies to mitigate the emergence of influenza antiviral resistance.
Keywords: Antiviral susceptibility; Baloxavir; Combination therapy; Influenza; Oseltamivir; PA-I38X.